Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MPI | P34949 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966187 | 0.87 | KCNH2 (0.47) | KMT2AHRH1KCNH2HTR1ADRD2 | |
| SCHEMBL2968152 | 0.83 | KCNH2 (0.47) | HRH1KCNH2HTR1ADRD2HTR2A | |
| SCHEMBL2967483 | 0.83 | KCNH2 (0.48) | KMT2AHRH1KCNH2HTR2ACCR3 | |
| SCHEMBL2967583 | 0.81 | KCNH2 (0.45) | KMT2AALDH1A1HRH1KCNH2DRD2 | |
| SCHEMBL2968141 | 0.80 | GRIN2B (0.45) | ALDH1A1LMNAMAPTHRH1KCNH2 | |
| SCHEMBL2966214 | 0.80 | KCNH2 (0.44) | KMT2AALDH1A1HRH1KCNH2DRD2 | |
| SCHEMBL2966847 | 0.80 | KCNH2 (0.46) | KMT2AKCNH2DRD2HTR2ADRD3 | |
| SCHEMBL2956846 | 0.78 | ALDH1A1 (0.48) | KMT2AALDH1A1LMNAMAPTKCNH2 | |
| SCHEMBL2966852 | 0.77 | KCNH2 (0.44) | KMT2AHRH1KCNH2DRD2DRD3 | |
| SCHEMBL2967662 | 0.77 | CHRM1 (0.45) | KMT2AKCNH2DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | claimed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | claimed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | claimed |
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003092720-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003092721-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | KMT2A 3826/4885ALDH1A1 321/4885LMNA 1110/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | KMT2A 3679/4885ALDH1A1 557/4885LMNA 1440/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KMT2A 3926/4885ALDH1A1 539/4885LMNA 969/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KMT2A 3980/4885ALDH1A1 534/4885LMNA 926/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | KMT2A 3926/4885ALDH1A1 539/4885LMNA 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.